Aernoud Fiolet

113 The LoDoCo2 trial rationale, design, and baseline characteristics 22. R.A. Terkeltaub, D.E. Furst, K. Bennett, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum, 62 (4) (2010), pp. 1060-1068 23. J. Kong, Y. Deng, Q. Dong, et al. Colchicine reduces restenosis after balloon angioplasty treatment for in-stent restenosis. Arch Med Res, 46 (2) (2015), pp. 101-106 24. S. Verma, J.W. Eikelboom, S.M. Nidorf, et al. Colchicine in cardiac disease: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord, 15 (96) (2015) 25. L.G. Hemkens, V.L. Gloy, K.K. Olu, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev, 2014 (3) (2014) 26. D.B. Crittenden, R.A. Lehmann, L. Schneck, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol, 39 (7) (2012), pp. 1458- 1464 27. D.H. Solomon, C.C. Liu, I.H. Kuo, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis, November (2015) 28. S. Deftereos, G. Giannopoulos, K. Raisakis, et al. Colchicine treatment for the prevention of bare- metal stent restenosis in diabetic patients. J Am Coll Cardiol, 61 (16) (2013), pp. 1679-1685 29. G.J. Martinez, S. Robertson, J. Barraclough, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc, 4 (8) (2015), Article e002128 30. S.M. Nidorf, J.W. Eikelboom, C.A. Budgeon, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol, 61 (4) (2013), pp. 404-410 31. Harada M, Van Wagoner DR NS. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015;79(3):495–502 32. M. Imazio, A. Brucato, P. Ferrazzi, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 124 (21) (2011), pp. 2290-2295 33. C.A. Dinarello, M.Y.M.-P.T. Donath. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Obes, 17 (4) (2010), pp. 314-321 34. B.R.C.S. Branchford. The role of inflammation in venous thromboembolism. Front Pediatr, 6 (142) (2018) 35. E.S. Stroes, P.D. Thompson, A. Corsini, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J, 36 (17) (2015), pp. 1012-1022 36. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. J Am Coll Cardiol. 2015;66(4):403–469. 37. K. Thygesen, J.S. Alpert, A.S. Jaffe, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol, 60 (16) (2012), pp. 1581-1598 38. ICH. ICH Harmonised Tripartite Guideline—Statistical Principles For Clinical Trials; 1998. 39. World Health Organisation (WHO). Top 10 causes of death worldwide. ttps://www.who.int/news- room/fact-sheets/detail/the-top-10-causes-of-death. Published 2018. Accessed March 10, 2019.